Q: What are the key findings of the recently published AIIDA study?
Q: 最近公布的AIIDA研究最重要的发现是什么？
A: The Acarbose action on low grade Inflammation and Immune response in type 2 Diabetes on Atherosclerosis risk (AIIDA) study investigated the association between acarbose treatment and postprandial metabolism， immune- and inflammatory activity in patients with early type 2 diabetes. After 20 weeks treatment， the leukocyte and lymphocyte (markers of sub-clinical inflammation and cellular immune response to food) excursion was significantly reduced with acarbose 4 hours after test meal. This mitigation of cellular immune response to food uptake may contribute to the preventive effect of acarbose on progression of glucose intolerance and vascular disease observed in the STOP-NIDDM trial and underlines the cardiovascular benefits of acarbose at a very early stage of the disease.
A: 在有动脉粥样硬化风险的2型糖尿病患者中，阿卡波糖对低度炎症和免疫反应的作用（The Acarbose action on low grade Inflammation and Immune response in type 2 Diabetes on Atherosclerosis risk，AIIDA) 研究观察了2型糖尿病早期患者采用阿卡波糖治疗与餐后代谢、免疫和炎症活性的相关性。研究结果显示，经过为期20周的治疗，阿卡波糖治疗使餐后4小时白细胞和淋巴细胞（亚临床炎症和细胞对食物产生免疫反应的标记物）的迁移显著减少。STOP-NIDDM研究观察到，阿卡波糖可以延缓糖尿病和血管病变的发生，究其原因可能与AIIDA研究发现的进食后细胞免疫反应下降有关，AIIDA研究结果提示早期应用阿卡波糖可能具有心血管保护效应。